Cinctive Capital Management LP Invests $8.16 Million in Amedisys, Inc. (NASDAQ:AMED)

Cinctive Capital Management LP acquired a new position in shares of Amedisys, Inc. (NASDAQ:AMED) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 89,822 shares of the health services provider’s stock, valued at approximately $8,155,000. Cinctive Capital Management LP owned about 0.27% of Amedisys as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of AMED. Charles Schwab Investment Management Inc. boosted its position in shares of Amedisys by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after buying an additional 9,004 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Amedisys by 15.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,781 shares of the health services provider’s stock valued at $654,000 after purchasing an additional 903 shares during the last quarter. Holocene Advisors LP increased its stake in shares of Amedisys by 391.4% during the 3rd quarter. Holocene Advisors LP now owns 79,036 shares of the health services provider’s stock worth $7,628,000 after purchasing an additional 62,953 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new position in shares of Amedisys during the 3rd quarter worth approximately $28,953,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Amedisys during the 3rd quarter worth approximately $371,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Up 0.2 %

Shares of AMED opened at $92.84 on Wednesday. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company’s fifty day moving average is $92.30 and its two-hundred day moving average is $92.35. The firm has a market cap of $3.05 billion, a PE ratio of 36.84, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The firm had revenue of $598.05 million for the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Stephens reissued an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $101.00.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.